Home > Insider Trading > Filing (0001104659-11-063254)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1316175	Anthera Pharmaceuticals Inc	ANTH	Pharmaceutical Preparations (2834)	201852016

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1314902	Colin Hislop	C/O Anthera Pharmaceuticals 25801 Industrial Blvd Suite B Hayward CA 94545	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-11-08	15,000	$0.26	72,967	No	4	M	Direct
Common Stock	Disposition	2011-11-08	15,000	$6.74	57,967	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option	Disposition	2011-11-08	15,000	$0.00	15,000	$0.26

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
90,447		2017-01-23	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	15,183	Indirect	By The Hislop-Burton Family Trust

Footnotes

This Stock Option, representing a right to purchase a total of 145,130 shares of common stock of the Issuer, was immediately exercisable on the date of the grant. However, all unvested shares underlying this Stock Option were subject to a right of repurchase held by the Issuer, which lapsed according to the following vesting schedule: 25% of the total number of shares vest on the first anniversary of the December 1, 2005 vesting start date (the "Vesting Start Date") and pro-rata monthly thereafter. This Stock Option became completely vested on the fourth anniversary of the Vesting Start Date.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.